

# SUVEN Life Sciences Ltd



## News Release

HYDERABAD, INDIA (July 12<sup>th</sup>, 2007)

**Suven Life Sciences files its first Investigational New Drug (IND) application of its NCE SUVN-502 in India to conduct Phase 1 clinical trials.**

**Suven Life Sciences submitted an application with Drug Controller General of India for grant of permission to undertake Phase-1 clinical trials with their Investigational New Drug (IND) SUVN-502.**

**SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT<sub>6</sub>, intended for the treatment of cognitive disorders such as Alzheimer's and Schizophrenia.**

**Treatment for Alzheimer's disease and Schizophrenia is an unmet medical need.** Suven's primary focus is to discover drugs that address significant unmet medical needs.

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven's discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven's CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders and Neurodegeneration.

Suven Life Sciences, a Hyderabad based Life Sciences Company, pioneer in **Contract Research And Manufacturing Services (CRAMS)** since 1995, **"Drug Discovery and Development Support Services" (DDDSS)** since 2005, and **Collaborative Research Partner (CRP)** with global pharma majors since 2006.

A focused provider of **CRAMS, DDDSS** and as a **CRP** for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 190 professionals with the state of the art infrastructure for Drug Discovery and development activities with 50 clinical research professionals and the front-end project management services from New Jersey, USA.

For more information on Suven, please visit our Web site at <http://www.suven.com>

### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;***